Want to see CTSO full AI Analyst Report?
CTSO Stock Chart & Stats
$0.36
>-$0.01(-0.06%)
At close: 4:00 PM EDT
$0.36
>-$0.01(-0.06%)
Day’s Range― - ―
52-Week Range$0.35 - $1.22
Previous CloseN/A
Volume48.92K
Average Volume (3M)134.35K
Market Cap
$22.68M
Enterprise Value$60.26
Total Cash (Recent Filing)$4.41M
Total Debt (Recent Filing)$26.33M
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Oct 29, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.29
Shares Outstanding62,842,747
10 Day Avg. Volume163,660
30 Day Avg. Volume134,354
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)6.74
Price to Sales (P/S)1.07
P/FCF Ratio-3.17
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$0.75Price Target Upside108.33% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-0.17
Revenue Forecast (FY)$39.37M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained ~70%+ gross margins reflect a capital-light, high-margin product (single-use cartridges) and manufacturing improvements. Durable margin strength supports operating leverage as sales scale, improving the odds of converting modest revenue growth into sustained profitability over 2–6 months.
Sharply Reduced Cash Burn; Breakeven PlanMeaningful decline in operating cash burn and management guidance to reach operating cash‑flow breakeven are durable operational improvements. If maintained, lower burn prolongs runway, reduces immediate financing dependence, and creates a clearer path to self-funded commercial expansion and margin recovery.
Active Regulatory Pathway & Breakthrough StatusConstructive FDA engagement and Breakthrough designations materially lower regulatory uncertainty versus a blank slate. A defined pathway using mechanistic data and RWE can expedite U.S. market access, enabling durable commercial upside if submissions succeed and broaden addressable market.
Bears Say
Weakened Balance SheetNegative equity and elevated debt materially reduce financial flexibility and raise refinancing risk. Over 2–6 months this constrains the company’s ability to invest in sales capacity or absorb setbacks, increasing likelihood of dilutive financings if operating cash flow does not convert to positive as guided.
Clinical/regulatory UncertaintyFailure to meet the primary endpoint forces reliance on subgroup analyses, complicating FDA benefit‑risk decisions, payer coverage, and physician adoption. This structural uncertainty raises the bar for evidence and could delay or limit market acceptance even with focused resubmissions.
Listing & Near‑term Funding RiskA Nasdaq compliance notice creates a material structural financing and execution risk over the next 2–6 months. Failure to cure could force emergency equity raises, disruptive listing outcomes, or constrained access to capital—each would heighten dilution risk and hamper long‑term commercial investments.
Cytosorbents News
CTSO FAQ
What was Cytosorbents Corp’s price range in the past 12 months?
Cytosorbents Corp lowest stock price was $0.35 and its highest was $1.22 in the past 12 months.
What is Cytosorbents Corp’s market cap?
Cytosorbents Corp’s market cap is $22.68M.
When is Cytosorbents Corp’s upcoming earnings report date?
Cytosorbents Corp’s upcoming earnings report date is Oct 29, 2026 which is in 80 days.
How were Cytosorbents Corp’s earnings last quarter?
Cytosorbents Corp released its earnings results on Aug 06, 2026. The company reported -$0.05 earnings per share for the quarter, missing the consensus estimate of -$0.04 by -$0.01.
Is Cytosorbents Corp overvalued?
According to Wall Street analysts Cytosorbents Corp’s price is currently Undervalued.
Does Cytosorbents Corp pay dividends?
Cytosorbents Corp does not currently pay dividends.
What is Cytosorbents Corp’s EPS estimate?
Cytosorbents Corp’s EPS estimate is -0.04.
How many shares outstanding does Cytosorbents Corp have?
Cytosorbents Corp has 62,842,747 shares outstanding.
What happened to Cytosorbents Corp’s price movement after its last earnings report?
Cytosorbents Corp reported an EPS of -$0.05 in its last earnings report, missing expectations of -$0.04. Following the earnings report the stock price went down -9.548%.
Which hedge fund is a major shareholder of Cytosorbents Corp?
Currently, no hedge funds are holding shares in CTSO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cytosorbents Corp
Cytosorbents Corporation specializes in creating and bringing to market innovative medical devices. Their core expertise lies in a unique blood purification platform, built upon a proprietary adsorbent and porous polymer technology. The company's leading product, CytoSorb, is an extracorporeal filter designed to remove cytokines from the blood. It serves as a complementary treatment in various critical care scenarios, including sepsis, managing complications during and after heart bypass surgery, and improving the viability of donor organs for transplantation. Beyond CytoSorb, Cytosorbents offers a portfolio of specialized devices. These include VetResQ, used to assist in treating critical conditions like sepsis and pancreatitis in animals; CytoSorb-XL, another device targeting sepsis and other severe illnesses; HemoDefend, a platform for purifying blood supplies by removing contaminants that cause transfusion reactions and diseases, as well as anti-A and anti-B antibodies from blood products; K+ontrol, designed for patients with severe, life-threatening hyperkalemia; and ContrastSorb, which extracts intravenous contrast agents following imaging procedures (like CT scans, angiograms, or interventional radiology) to mitigate the risk of contrast-induced kidney damage. The company is also actively developing several new solutions: BetaSorb, aimed at preventing and treating complications from metabolic toxin buildup in chronic kidney disease patients; DrugSorb, which focuses on eliminating harmful chemicals from the bloodstream; and DrugSorb-ATR, an innovative system for removing antithrombotic agents. Originally established as MedaSorb Technologies Corporation in 1997, the company adopted its current name, Cytosorbents Corporation, in May 2010. Its corporate headquarters are situated in Princeton, New Jersey.
CTSO Company Deck
CTSO Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a balanced mix of operational progress and material challenges. Positives include stable revenue (~$9.6M), improved gross margin (73%), reduced operating loss (down ~27%), meaningful adjusted metric improvements (adjusted EBITDA loss down ~38%), lower cash burn (net operating burn ~ $200k excluding restructuring) and encouraging safety/efficacy signals and regulatory engagement for DrugSorb-ATR (publication, safety profile, significant subset results and a defined FDA path). Offsetting these are the missed primary efficacy endpoint in the mITT population, the FDA's prior de novo denial (appeal upheld) requiring additional mechanistic and RWE data, protocol imbalances in STAR-T that complicate interpretation, market headwinds in Germany and the Middle East, a modest cash balance (~$5.9M) and continued net losses. Given the meaningful operational and clinical positives tempered by substantive regulatory, clinical robustness and funding risks, the overall tone is balanced.View all CTSO earnings summariesCTSO Stock 12 Month Forecast
Average Price Target
$0.75
▲(108.33% Upside)
Technical Analysis
Electrocore
―
TELA Bio
―
Spectral AI
―
Icecure Medical
―
Baird Medical Investment Holdings
―
Ownership Overview
3.79% Insiders
6.65% Mutual Funds
2.30% Other Institutional Investors
84.29% Public Companies and
Individual Investors